Quick Answer
Candel Therapeutics, Inc. reported Cash and Equivalents of $119.73 million for fiscal year 2025.
Candel Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $119.73M | +16.6% |
| 2024 | $102.65M | +189.9% |
| 2023 | $35.41M | -49.5% |
| 2022 | $70.06M | -15.2% |
| 2021 | $82.64M | +135.8% |
| 2020 | $35.05M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $86.96M | +425.2% | -13.6% |
| June 30, 2025 | $100.69M | +369.3% | +9.2% |
| March 31, 2025 | $92.17M | +258.4% | -10.2% |
| December 31, 2024 | $102.65M | +189.9% | +520.0% |
| September 30, 2024 | $16.56M | -61.5% | -22.8% |
| June 30, 2024 | $21.45M | -58.7% | -16.6% |
| March 31, 2024 | $25.71M | -56.6% | -27.4% |
| December 31, 2023 | $35.41M | -49.5% | -17.6% |
- Candel Therapeutics, Inc. showed an increase of +16.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Candel Therapeutics, Inc.’s cash and equivalents has grown by 241.6% (from $35.05 million to $119.73 million).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: